CompletedPhase 2NCT01207492

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

Studying Tenosynovial giant cell tumor

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Andrew J. Wagner, MD, PhD
Principal Investigator
Andrew J. Wagner, MD, PhD
Dana-Farber Cancer Institute
Intervention
nilotinib(drug)
Enrollment
17 target
Eligibility
18 years · All sexes
Timeline
20102015

Study locations (7)

Collaborators

Brigham and Women's Hospital · Massachusetts General Hospital · Novartis

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01207492 on ClinicalTrials.gov

Other trials for Tenosynovial giant cell tumor

Additional recruiting or active studies for the same condition.

See all trials for Tenosynovial giant cell tumor

← Back to all trials